LSE - LSE Delayed price. Currency in PLN


ul. Forteczna 35-37
Torun 87-100
48 56 669 4000

Full-time employees3,981

Key executives

NameTitlePayExercisedYear born
Mr. Piotr SucharskiPres of the Management Board & Gen. Director2.29MN/AN/A
Mr. Grzegorz DzikVP of Management Board & CFO1.29MN/AN/A
Mr. Krzysztof MiszewskiVP of Management Board for Operations1.5MN/AN/A
Mr. Daniel WojtkiewiczVP of the Management BoardN/AN/AN/A
Ms. Julita CzyzewskaVP of the Management BoardN/AN/AN/A
Mr. Roman DudzikVP of the Management BoardN/AN/AN/A
Beata KorzeniewskaGroup PR DirectorN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in PLN.


NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and Telemedicine segments. The company also provides advertising and marketing services; pharmaceutical products under its own brand; clinical trial, telemedicine, agency, financial, road cargo transport, accounting and bookkeeping, software, hospital, and information technology and computer related services; and health, property, and other personal insurance products. In addition, it operates outpatient care clinics and medical stores. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.

Corporate governance

NEUCA S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.